Recently, the U.S. Food and Drug Administration has issued an emergency use authorization for remdesivir. The treatment has been indicated for the use in suspected or laboratory-confirmed COVID-19 cases in adults and children hospitalized with severe disease conditions. While there is limited information on the safety and efficacy of this drug, it has demonstrated a reduction of symptoms and prognosis in some patients.
The USFDA has authorized the emergency use of remdesivir, a broad-spectrum antiviral drug after it showed promising results in fighting COVID-19 by shortening the recovery time of the patients. The emergency use authorization (EUA) allows the distribution of remdesivir in the U.S., and its intravenous administration under the supervision of health care providers to treat severe cases of COVID-19 infection. This is applicable for patients who need ventilator support due to…
